After an ankle sprain, the swelling and bruising usually settle within weeks. For some people, though, pain lingers — and this can sometimes be linked to wear within the joint rather than the ligaments alone. This article looks at what causes persistent ankle pain after a sprain, when the ChondroFiller injection may be an appropriate non-surgical option, and when a more involved approach is worth discussing.

When a Sprain Is More Than a Ligament Injury

A lateral ankle sprain is one of the most common musculoskeletal injuries, yet the same force that stretches or tears the ligaments can also affect the cartilage lining the joint. The talus — the bone that sits at the base of the ankle — carries substantial load across a relatively small surface, and its cartilage has a limited capacity for self-repair owing to its poor blood supply. When a sprain damages the cartilage surface or dislodges a small fragment, the result can be an osteochondral lesion of the talus: a defect that may cause ongoing ache, swelling, a sense of instability, or a catching sensation that does not settle in the weeks following injury.

Symptoms that persist beyond six to eight weeks after a sprain — particularly deep joint ache, swelling that recurs with activity, or an inability to fully weight-bear without discomfort — are worth investigating properly. Imaging, typically an MRI, helps identify whether there is cartilage involvement and guides decisions about management.

What Is the ChondroFiller Injection?

ChondroFiller is a CE-marked Class III medical device: a type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany. When delivered into a joint it self-gels within a few minutes, forming a porous three-dimensional matrix that provides physical support over a worn or defective surface and recruits the body's own progenitor cells to begin rebuilding the tissue.

The ChondroFiller injection is the non-surgical delivery pathway for this scaffold. It is administered as an ultrasound-guided outpatient injection — no theatre, no general anaesthetic, and no incision. The gel settles over the worn area, adding a protective, cushioning layer that may reduce grinding and provide a biological environment supportive of tissue repair. Precise placement under ultrasound guidance matters; it is not a standard cortisone or viscosupplementation injection.

It is best understood as a regenerative, joint-preserving option rather than a cure. It does not reverse established arthritis, and benefits vary between patients. Appropriate selection — based on the size and depth of any defect, joint alignment, and overall joint health — is essential.

What the Evidence Suggests

Clinical experience with collagen-matrix injections for ankle cartilage is encouraging, though the evidence base is still developing. Many patients report improved comfort and function, and the safety profile is reassuring. A 2023 study in the journal Cartilage reported improvements in pain and grip strength following ChondroFiller treatment of thumb-base osteoarthritis (Corain M, Zanotti F, Giardini M, et al. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023), providing early evidence of efficacy in small-joint applications. Responses vary, and benefits cannot be guaranteed for any individual.

When Surgery May Be More Appropriate: Liquid Cartilage

The ChondroFiller injection is suited to accessible lesions, smaller defects, and situations where avoiding theatre is a priority. For larger or more complex osteochondral defects of the talus — particularly those that have not responded to conservative measures — a surgical approach may offer a more durable solution.

At the London Cartilage Clinic, Professor Paul Lee has developed the Liquid Cartilage surgical protocol, a keyhole (arthroscopic) technique that places the ChondroFiller scaffold into the defect under dry conditions within the joint, combined with biological adjuncts including platelet-rich fibrin, platelet-rich plasma, and tranexamic acid. Where indicated, the patient's own mesenchymal stem cells from bone-marrow aspirate concentrate or micro-fragmented fat may be added to support chondrogenesis. This is genuine surgery, performed under anaesthetic in theatre, with a structured rehabilitation programme afterwards — it is a different pathway from the injection, not a different name for the same thing.

Which pathway is appropriate depends on the defect size and depth, the degree of any underlying bone involvement, and the patient's overall joint health and priorities. An experienced clinician can help determine this after reviewing imaging.

What to Expect and Next Steps

Persistent ankle pain after a sprain deserves proper assessment rather than reassurance alone. If imaging confirms cartilage involvement, the range of options — from the ChondroFiller injection through to the Liquid Cartilage surgical protocol — can be discussed in the context of your specific findings.

At the London Cartilage Clinic, assessment combines clinical examination with careful imaging review to provide a clear picture of what is happening within the joint and realistic guidance on which options are worth considering. If you are still struggling with ankle pain weeks or months after a sprain, a consultation is a sensible starting point.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.